228 related articles for article (PubMed ID: 30160301)
1. Recovery of respiratory function in mdx mice co-treated with neutralizing interleukin-6 receptor antibodies and urocortin-2.
Burns DP; Canavan L; Rowland J; O'Flaherty R; Brannock M; Drummond SE; O'Malley D; Edge D; O'Halloran KD
J Physiol; 2018 Nov; 596(21):5175-5197. PubMed ID: 30160301
[TBL] [Abstract][Full Text] [Related]
2. Restoration of pharyngeal dilator muscle force in dystrophin-deficient (mdx) mice following co-treatment with neutralizing interleukin-6 receptor antibodies and urocortin 2.
Burns DP; Rowland J; Canavan L; Murphy KH; Brannock M; O'Malley D; O'Halloran KD; Edge D
Exp Physiol; 2017 Sep; 102(9):1177-1193. PubMed ID: 28665499
[TBL] [Abstract][Full Text] [Related]
3. Combined XIL-6R and urocortin-2 treatment restores MDX diaphragm muscle force.
Manning J; Buckley MM; O'Halloran KD; O'Malley D
Muscle Nerve; 2017 Dec; 56(6):E134-E140. PubMed ID: 28294390
[TBL] [Abstract][Full Text] [Related]
4. Sensorimotor control of breathing in the mdx mouse model of Duchenne muscular dystrophy.
Burns DP; Roy A; Lucking EF; McDonald FB; Gray S; Wilson RJ; Edge D; O'Halloran KD
J Physiol; 2017 Nov; 595(21):6653-6672. PubMed ID: 28952155
[TBL] [Abstract][Full Text] [Related]
5. Inspiratory pressure-generating capacity is preserved during ventilatory and non-ventilatory behaviours in young dystrophic mdx mice despite profound diaphragm muscle weakness.
Burns DP; Murphy KH; Lucking EF; O'Halloran KD
J Physiol; 2019 Feb; 597(3):831-848. PubMed ID: 30570134
[TBL] [Abstract][Full Text] [Related]
6. N-acetylcysteine Decreases Fibrosis and Increases Force-Generating Capacity of
Burns DP; Drummond SE; Bolger D; Coiscaud A; Murphy KH; Edge D; O'Halloran KD
Antioxidants (Basel); 2019 Nov; 8(12):. PubMed ID: 31771272
[TBL] [Abstract][Full Text] [Related]
7. In vivo neutralization of IL-6 receptors ameliorates gastrointestinal dysfunction in dystrophin-deficient mdx mice.
Manning J; Buckley MM; O'Halloran KD; O'Malley D
Neurogastroenterol Motil; 2016 Jul; 28(7):1016-26. PubMed ID: 26920808
[TBL] [Abstract][Full Text] [Related]
8. Validation of ultrasonography for non-invasive assessment of diaphragm function in muscular dystrophy.
Whitehead NP; Bible KL; Kim MJ; Odom GL; Adams ME; Froehner SC
J Physiol; 2016 Dec; 594(24):7215-7227. PubMed ID: 27570057
[TBL] [Abstract][Full Text] [Related]
9. Loss of compensation afforded by accessory muscles of breathing leads to respiratory system compromise in the mdx mouse model of Duchenne muscular dystrophy.
O'Halloran KD; Maxwell MN; Marullo AL; Hamilton CP; Ó Murchú SC; Burns DP; Mahony CM; Slyne AD; Drummond SE
J Physiol; 2023 Oct; 601(19):4441-4467. PubMed ID: 37688347
[TBL] [Abstract][Full Text] [Related]
10. Respiratory Control in the mdx Mouse Model of Duchenne Muscular Dystrophy.
Burns DP; Edge D; O'Malley D; O'Halloran KD
Adv Exp Med Biol; 2015; 860():239-44. PubMed ID: 26303487
[TBL] [Abstract][Full Text] [Related]
11. The slow-release adiponectin analog ALY688-SR modifies early-stage disease development in the D2.
Bellissimo CA; Gandhi S; Castellani LN; Murugathasan M; Delfinis LJ; Thuhan A; Garibotti MC; Seo Y; Rebalka IA; Hsu HH; Sweeney G; Hawke TJ; Abdul-Sater AA; Perry CGR
Am J Physiol Cell Physiol; 2024 Apr; 326(4):C1011-C1026. PubMed ID: 38145301
[TBL] [Abstract][Full Text] [Related]
12. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
Percival JM; Whitehead NP; Adams ME; Adamo CM; Beavo JA; Froehner SC
J Pathol; 2012 Sep; 228(1):77-87. PubMed ID: 22653783
[TBL] [Abstract][Full Text] [Related]
13. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
[TBL] [Abstract][Full Text] [Related]
14. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
[TBL] [Abstract][Full Text] [Related]
15. Dystrophic mdx mice develop severe cardiac and respiratory dysfunction following genetic ablation of the anti-inflammatory cytokine IL-10.
Nitahara-Kasahara Y; Hayashita-Kinoh H; Chiyo T; Nishiyama A; Okada H; Takeda S; Okada T
Hum Mol Genet; 2014 Aug; 23(15):3990-4000. PubMed ID: 24659498
[TBL] [Abstract][Full Text] [Related]
16. IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouse.
Kostek MC; Nagaraju K; Pistilli E; Sali A; Lai SH; Gordon B; Chen YW
BMC Musculoskelet Disord; 2012 Jun; 13():106. PubMed ID: 22716658
[TBL] [Abstract][Full Text] [Related]
17. Diaphragm muscle fibrosis involves changes in collagen organization with mechanical implications in Duchenne muscular dystrophy.
Sahani R; Wallace CH; Jones BK; Blemker SS
J Appl Physiol (1985); 2022 Mar; 132(3):653-672. PubMed ID: 35050792
[TBL] [Abstract][Full Text] [Related]
18. Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice.
Wada E; Tanihata J; Iwamura A; Takeda S; Hayashi YK; Matsuda R
Skelet Muscle; 2017 Oct; 7(1):23. PubMed ID: 29078808
[TBL] [Abstract][Full Text] [Related]
19. Force and power output of diaphragm muscle strips from mdx and control mice after clenbuterol treatment.
Lynch GS; Hinkle RT; Faulkner JA
Neuromuscul Disord; 2001 Mar; 11(2):192-6. PubMed ID: 11257477
[TBL] [Abstract][Full Text] [Related]
20. AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy.
Abou-Samra M; Selvais CM; Boursereau R; Lecompte S; Noel L; Brichard SM
J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):518-533. PubMed ID: 31965757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
